Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis
Authors' conclusion
Romosozumab could improve bone mass and bone quality, measured by TBS, in postmenopausal osteoporosis, particularly as a subsequent regimen in patients previously taking anti-resorptive agents.
Study context
- Population
- Postmenopausal women starting romosozumab or denosumab, Severance Hospital, Korea (age 64 years; previous fracture 38%; prior bisphosphonate or selective estrogen receptor modulator (SERM) exposure 50%)174 analysed
- Participants
- 174 women
- Exposure
- Romosozumab vs denosumab
- Romosozumabn = 87
- Denosumabn = 87reference
- Outcome
- Change in spinal trabecular bone score (TBS)
Methodological detailspropensity-score matched (1:1), single-centre
- Propensity-score matched (1:1)
- Single-centre
Main finding
As reported in the abstract
TBS increase
P = 0.013
Observational data: associations, not effects.
Further findings
Lumbar spine BMD increase
P < 0.001
TBS improvement in patients transitioning from bisphosphonate or SERM (subgroup)
P = 0.006
TBS improvement in drug-naive patients (subgroup) · no significant difference
P = 0.472
Good responders (TBS improvement ≥5.8%) · 12 months
P = 0.024
| Outcome | aOR | P value |
|---|---|---|
| Good responders (TBS improvement ≥5.8%) · 12 monthsAfter covariate adjustment | 3.85 | P = 0.002 |
Original publication
Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis. Osteoporos Int. Published 19 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →